Skip to main content
. 2023 May 12;31(6):226–237. doi: 10.1007/s12471-023-01776-1

Fig. 3.

Fig. 3

Cost-effectiveness plane of different interventions for hypertrophic and dilated cardiomyopathy. Cost-effectiveness plane with willingness to pay (WTP) thresholds of € 50,000 and € 100,000 per quality adjusted life-year (QALY) gained: ● Diagnostics in hypertrophic cardiomyopathy in QALYs; ■ Treatments for hypertrophic cardiomyopathy in QALYs; ▲ Diagnostics in dilated cardiomyopathy in QALYs; ♦ Treatments for dilated cardiomyopathy in QALYs